Treatment of higher-risk myelodysplastic syndrome

Seminars in Oncology

Volumn 38, Issue 5, 2011, Pages 673-681

  Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CLOFARABINE; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MOCETINOSTAT; SAPACITABINE; SBIO 939; SGI 110; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DNA METHYLATION; DRUG MECHANISM; HIGH RISK PATIENT; HUMAN; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; AZACITIDINE; COMBINED MODALITY THERAPY; DNA METHYLATION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MYELODYSPLASTIC SYNDROMES; PATIENT SELECTION; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 80053209138     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.07.001     Document Type: Article

References (51)

1. P. Greenberg, C. Cox, and M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088 (Pubitemid 27132124)
2. D.E. Rollison, N. Howlader, and M.T. Smith Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs Blood 112 2008 45 52
3. M. Albitar, T. Manshouri, and Y. Shen Myelodysplastic syndrome is not merely "preleukemia" Blood 100 2002 791 798 (Pubitemid 34832603)
4. H. Kantarjian, J.P. Issa, and C.S. Rosenfeld Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 2006 1794 1803
5. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 2009 223 232
6. K.D. Robertson, and A.P. Wolffe DNA methylation in health and disease Nat Rev Genet 1 2000 11 19
7. P.A. Jones, and S.B. Baylin The epigenomics of cancer Cell 128 2007 683 692 (Pubitemid 46273572)
8. L. Shen, H. Kantarjian, and Y. Guo DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes J Clin Oncol 28 2010 605 613
9. L.R. Silverman, E.P. Demakos, and B.L. Peterson Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B J Clin Oncol 20 2002 2429 2440 (Pubitemid 34525728)
10. G. Garcia-Manero, H.M. Kantarjian, and B. Sanchez-Gonzalez Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia Blood 108 2006 3271 3279
11. L.R. Silverman, D.R. McKenzie, and B.L. Peterson Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 24 2006 3895 3903 (Pubitemid 46630737)
12. A.B. Kornblith, J.E. Herndon 2nd, and L.R. Silverman Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study J Clin Oncol 20 2002 2441 2452 (Pubitemid 34525729)
13. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia J Clin Oncol 28 2010 562 569
14. J.P. Issa, G. Garcia-Manero, and F.J. Giles Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640 (Pubitemid 38268953)
15. H. Kantarjian, Y. Oki, and G. Garcia-Manero Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 2007 52 57 (Pubitemid 46053042)
16. M.A. Sekeres, and D.P. Steensma Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment Blood 114 2009 2575 2580
17. M. Lubbert, S. Suciu, and L. Baila Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group J Clin Oncol 29 2011 1987 1996
18. D.P. Steensma, M.R. Baer, and J.L. Slack Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the Alternative Dosing for Outpatient Treatment (ADOPT) trial J Clin Oncol 27 2009 3842 3848
19. L.R. Silverman, P. Fenaux, and G.J. Mufti Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes Cancer 117 2011 2697 2702
20. A.O. Soriano, H. Yang, and S. Faderl Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 110 2007 2302 2308 (Pubitemid 47523148)
21. T. Kadia, Z. Estrov, and F. Ravandi Long term followup and patterns of failure in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) treated on studies combining a hypomethylating agent and the histone deacetylase inhibitor (HDACi) valproic acid Blood 114 2009 2074
22. T.E. Fandy, J.G. Herman, and P. Kerns Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies Blood 114 2009 2764 2773
23. R. Itzykson, O. Kosmider, and T. Cluzeau Presence of TET2 mutation predicts a higher response rate to azacitidine in MDS and AML post MDS [abstract 439] Blood 2010
24. W. Blum, R. Garzon, and R.B. Klisovic Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine Proc Natl Acad Sci U S A 107 2010 7473 7478
25. M. Ko, Y. Huang, and A.M. Jankowska Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 Nature 468 2010 839 843
26. O. Abdel-Wahab, A. Mullally, and C. Hedvat Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Blood 114 2009 144 147
27. F. Delhommeau, S. Dupont, and V. Della Valle Mutation in TET2 in myeloid cancers N Engl J Med 360 2009 2289 2301
28. S.M. Langemeijer, R.P. Kuiper, and M. Berends Acquired mutations in TET2 are common in myelodysplastic syndromes Nat Genet 41 2009 838 842
29. R. Itzykson, O. Kosmider, and T. Cluzeau Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias Leukemia 25 2011 1147 1152
30. H. Yang, Z. Fang, and Y. Wei Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA Am J Hematol 86 2011 237 238
31. R. Itzykson, S. Thepot, and B. Quesnel Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine Blood 117 2011 403 411
32. E. Wattel, S. De Botton, and J. Luc Lai Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders Br J Haematol 98 1997 983 991 (Pubitemid 27421645)
33. M. Beran, Y. Shen, and H. Kantarjian High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens Cancer 92 2001 1999 2015 (Pubitemid 32973307)
34. E.H. Estey, S. Pierce, and M.J. Keating Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities Haematologica 85 2000 246 249 (Pubitemid 30340139)
35. C. Chang, B.E. Storer, and B.L. Scott Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders Blood 110 2007 1379 1387 (Pubitemid 47281440)
36. C.S. Cutler, S.J. Lee, and P. Greenberg A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 2004 579 585 (Pubitemid 38900045)
37. G. Garcia-Manero, S.D. Gore, and C. Cogle Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia J Clin Oncol 29 2011 2521 2527
38. E.E. Cameron, K.E. Bachman, and S. Myohanen Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 21 1999 103 107 (Pubitemid 29036293)
39. H. Yang, K. Hoshino, and B. Sanchez-Gonzalez Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid Leuk Res 29 2005 739 748 (Pubitemid 40779480)
40. A. Kuendgen, M. Schmid, and S. Knipp Valproic acis achieves hugh response rates in patients with low-risk myelodysplastic syndromes Blood 106 2005 233a
41. G. Garcia-Manero, H. Yang, and C. Bueso-Ramos Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood 111 2008 1060 1066 (Pubitemid 351213383)
42. G. Garcia-Manero, S. Assouline, and J. Cortes Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 112 2008 981 989
43. I. Gojo, A. Jiemjit, and J.B. Trepel Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood 109 2007 2781 2790 (Pubitemid 46482071)
44. F. Giles, T. Fischer, and J. Cortes A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies Clin Cancer Res 12 2006 4628 4635 (Pubitemid 44297814)
45. W. Blum, R.B. Klisovic, and B. Hackanson Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia J Clin Oncol 25 2007 3884 3891 (Pubitemid 47477265)
46. Issa J, Castoro R, Ravandi-Kashani F, et al. Randomized phase II study of combined epigenetic therapy: decitabine vs. decitabine and valproic acid in MDS and AML. Blood. 208;112:228.
47. M.A. Sekeres, A.F. List, and D. Cuthbertson Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes J Clin Oncol 28 2010 2253 2258
48. R. Vij, A. Nelson, and G. Uy A phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients > 60 years old Blood 114 2009 842
49. R. Bejar, R. Levine, and B.L. Ebert Unraveling the molecular pathophysiology of myelodysplastic syndromes J Clin Oncol 29 2011 504 515
50. S. Faderl, G. Garcia-Manero, and Z. Estrov Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome J Clin Oncol 28 2010 2755 2760
51. H. Kantarjian, G. Garcia-Manero, and S. O'Brien Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome J Clin Oncol 28 2011 285 291